PHI AB’s warrant exercise registered at the Swedish Companies Registration Office
Phase Holographic Imaging PHI AB ("PHI" or "Company") today announces that the new shares from the exercise of warrants of series TO 4 have been registered at the Swedish Companies Registration Office.
On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with PHI’s rights issue of units in 2022, ended. As a result of the warrant exercise, 1,129,513 new shares have now been registered with the Swedish Companies Registration Office. The total number of shares in the Company after the exercise of warrants of series TO 4 amounts to 27,322,438 and the share capital amounts to SEK 5,464,487.60.
Conversion of interim shares to ordinary shares takes place around 25 October 2024 and ordinary shares are expected to be visible on each subscriber's depository account approximately two banking days thereafter.
Advisors
In connection with the warrant exercise, PHI has engaged Sedermera Corporate Finance AB as financial advisor, Foyen Advokatfirma i Sverige AB as legal advisor and Nordic Issuing AB as issuing agent.
For more information about the warrants, please contact:
Sedermera Corporate Finance AB
Tel: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
Web: www.sedermera.se
For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.